tadalafil has been researched along with Diabetic Angiopathies in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akdeniz, E; Aşcı, R; Bolat, MS; Cinar, O | 1 |
| Fogelstrand, P; Jansson, PA; Mattsson Hultén, L; Mobini, R; Olausson, J; Sjögren, L; Strindberg, L | 1 |
| Caruso, S; Cicero, C; Lo Presti, L; Malandrino, C; Romano, M; Ventura, B | 1 |
| Jansson, PA; Lönnroth, P; Murdolo, G; Sjöstrand, M; Strindberg, L | 1 |
| Calogero, AE; Cannizzaro, MA; Condorelli, R; La Vignera, S; Noto, Z; Vicari, E | 1 |
| Nini, A; Vardi, M | 1 |
1 review(s) available for tadalafil and Diabetic Angiopathies
| Article | Year |
|---|---|
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetic Angiopathies; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |
5 trial(s) available for tadalafil and Diabetic Angiopathies
| Article | Year |
|---|---|
Low dose daily versus on-demand high dose tadalafil in diabetic patients with erectile and ejaculatory dysfunction.
Topics: Aged; Diabetic Angiopathies; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Retrospective Studies; Tadalafil; Treatment Outcome | 2018 |
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelial Cells; Female; Forearm; Humans; Insulin Resistance; Male; Meals; Middle Aged; Phosphodiesterase 5 Inhibitors; Postprandial Period; Regional Blood Flow; Tadalafil; Treatment Outcome | 2016 |
Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder.
Topics: Adult; Arousal; Carbolines; Clitoris; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Drug Administration Schedule; Female; Humans; Orgasm; Premenopause; Prospective Studies; Quality of Life; Sexual Behavior; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Tadalafil; Vasodilator Agents; Young Adult | 2012 |
The selective phosphodiesterase-5 inhibitor tadalafil induces microvascular and metabolic effects in type 2 diabetic postmenopausal females.
Topics: Adipose Tissue; Body Composition; Carbolines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Microdialysis; Microvessels; Middle Aged; Muscle, Skeletal; Neovascularization, Pathologic; Phosphodiesterase 5 Inhibitors; Postmenopause; Substrate Specificity; Tadalafil | 2013 |
Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment.
Topics: Aged; Alprostadil; Arteries; Attitude to Health; Blood Flow Velocity; Carbolines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Erectile Dysfunction; Humans; Injections; Luteinizing Hormone; Male; Middle Aged; Nitric Oxide; Penis; Prolactin; Surveys and Questionnaires; Tadalafil; Testosterone; Treatment Outcome; Vasodilator Agents | 2006 |
1 other study(ies) available for tadalafil and Diabetic Angiopathies
| Article | Year |
|---|---|
[Risk classification assures safety].
Topics: Carbolines; Clinical Trials as Topic; Contraindications; Diabetic Angiopathies; Heart Diseases; Humans; Hypertension; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Risk Assessment; Tadalafil | 2003 |